Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)
Core Viewpoint - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) experienced a decline of approximately 20% on Monday despite receiving FDA approval for its fibromyalgia therapy, Tonmya, which had previously caused a surge in share prices [1]. Company Summary - Tonix Pharmaceuticals received FDA approval for its fibromyalgia therapy, Tonmya, on Friday [1]. - The approval initially led to a significant increase in share prices, but the stock fell by about 20% the following Monday [1].